Search Results - "Houédé, N"

Management of patients with systemic treatments by Houédé, N

“…To date, systemic treatments, including hormone therapies or chemotherapy, are used at different stages of prostate cancer disease. Several types of…”
Get more information

Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment by Pouessel, D., Neuzillet, Y., Mertens, L.S., van der Heijden, M.S., de Jong, J., Sanders, J., Peters, D., Leroy, K., Manceau, A., Maille, P., Soyeux, P., Moktefi, A., Semprez, F., Vordos, D., de la Taille, A., Hurst, C.D., Tomlinson, D.C., Harnden, P., Bostrom, P.J., Mirtti, T., Horenblas, S., Loriot, Y., Houédé, N., Chevreau, C., Beuzeboc, P., Shariat, S.F., Sagalowsky, A.I., Ashfaq, R., Burger, M., Jewett, M.A.S., Zlotta, A.R., Broeks, A., Bapat, B., Knowles, M.A., Lotan, Y., van der Kwast, T.H., Culine, S., Allory, Y., van Rhijn, B.W.G.

“…Fibroblast growth factor receptor 3 (FGFR3) is an actionable target in bladder cancer. Preclinical studies show that anti-FGFR3 treatment slows down tumor…”
Get full text

Characterization of prostate neuroendocrine cancers and therapeutic management: a literature review by Sargos, P, Ferretti, L, Gross-Goupil, M, Orre, M, Cornelis, F, Henriques de Figueiredo, B, Houédé, N, Merino, C, Roubaud, G, Dallaudiére, B, Richaud, P, Fléchon, A

“…Objectives: Neuroendocrine prostate cancers (NEPCs) are rare. The current lack of consensus for clinical, biological and pathological characterization as well…”
Get full text

Epicure: a European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapy by Houédé, N, Locker, G, Lucas, C, Parra, H Soto, Basso, U, Spaeth, D, Tambaro, R, Basterretxea, L, Morelli, F, Theodore, C, Lusuardi, L, Lainez, N, Guillot, A, Tonini, G, Bielle, J, Del Muro, X Garcia

“…Platinum-based systemic chemotherapy is considered the backbone for management of advanced urothelial carcinomas. However there is a lack of real world data on…”
Get full text

Intravesical adjuvant regimen of epitubicin for intermediate risk NMIBC: Feasability study from CC-AFU vessie by Rollin, P, Xylinas, E, Lanz, C, Audenet, F, Brunelle, S, Compérat, E, Houédé, N, Larré, S, Masson-Lecomte, A, Pignot, G, Roumiguié, M, Méjean, A, Rouprêt, M, Neuzillet, Y

“…Mitomycin C is the gold standard intravesical adjuvant therapy for intermediate-risk non-muscle-invasive bladder cancer (NMIBC). Tensions in the supply of…”
Get more information

Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project by Kramar, A., Negrier, S., Sylvester, R., Joniau, S., Mulders, P., Powles, T., Bex, A., Bonnetain, F., Bossi, A., Bracarda, S., Bukowski, R., Catto, J., Choueiri, T.K., Crabb, S., Eisen, T., El Demery, M., Fitzpatrick, J., Flamand, V., Goebell, P.J., Gravis, G., Houédé, N., Jacqmin, D., Kaplan, R., Malavaud, B., Massard, C., Melichar, B., Mourey, L., Nathan, P., Pasquier, D., Porta, C., Pouessel, D., Quinn, D., Ravaud, A., Rolland, F., Schmidinger, M., Tombal, B., Tosi, D., Vauleon, E., Volpe, A., Wolter, P., Escudier, B., Filleron, T., Kramar, Andrew, Sylvester, Richard, Filleron, Thomas, Negrier, Sylvie, Joniau, Steven, Mulders, Peter, Powles, Thomas, Escudier, Bernard, Bex, Axel, Bonnetain, Franck, Bossi, Alberto, Braccarda, Sergio, Bukowski, Ronald, Catto, James, Choueiri, Toni, Crabb, Simon, Eisen, Tim, El Demery, Mounira, Fitzpatrick, John, Flamand, Vincent, Goebell, Peter J., Gravis, Gwendael, Houédé, Nadine, Jacqmin, Didier, Kaplan, Richard, Malavaud, Bernard, Massard, Christophe, Melichar, Bohuslav, Mourey, Loïc, Nathan, Paul, Pasquier, David, Porta, Camillo, Pouessel, Damien, Quinn, David, Ravaud, Alain, Rolland, Frédéric, Schmidinger, Manuela, Tombal, Bertrand, Tosi, Diego, Vauleon, Elodie, Volpe, Alessandro, Wolter, Pascal

“…In clinical trials, the use of intermediate time-to-event end points (TEEs) is increasingly common, yet their choice and definitions are not standardized. This…”
Get full text

Statistical controversies in clinical research: should schedules of tumor size assessments be changed? by Filleron, T., Kouokam, W., Gilhodes, J., Duhamel, A., Penel, N., Joly, F., Tresch-Bruneel, E., Kramar, A., Houédé, N.

“…Time to progression (TTP) is often used as a primary end point in phase II clinical trials. Since the actual date of nadir and progression is never known, most…”
Get full text

Hemorrhagic cystitis in patients treated with cabazitaxel: a radiation recall syndrome? by Grellety, T., Houédé, N., Hoepffner, J.L., Rivière, J., Mérino, C., Lieutenant, V., Gross-Goupil, M., Richaud, P., Dupin, C., Sargos, P., Roubaud, G.

Get full text

ypT0N0 after neoadjuvant chemotherapy and cystectomy for muscle-invasive bladder cancer: Incidence and prognosis. A review from the Bladder group of the French Committee of Oncology by Pignot, G, Houédé, N, Roumiguié, M, Audenet, F, Brunelle, S, Colin, P, Compérat, E, Larré, S, Masson-Lecomte, A, Neuzillet, Y, Xylinas, E, Méjean, A, Rouprêt, M

“…Neoadjuvant chemotherapy (NAC) is recommended for localized muscle-invasive bladder cancer when patients are fit for cisplatin-based chemotherapy. A…”
Get more information

Tasquinimod: How to act on microenvironment in metastatic prostate cancer by Houédé, N, Irani, J

“…Despite the recent introduction of new drugs, castration-resistant metastatic prostate cancer, (mCRPC) remains a poor prognosis disease, with a crucial need…”
Get more information

CCAFU french national guidelines 2016-2018 on bladder cancer by Rouprêt, M, Neuzillet, Y, Masson-Lecomte, A, Colin, P, Compérat, E, Dubosq, F, Houédé, N, Larré, S, Pignot, G, Puech, P, Roumiguié, M, Xylinas, E, Méjean, A

“…The purpose of the guidelines national committee CCAFU on bladder cancer was to propose updated french guidelines for non-muscle invasive (NMIBC) and invasive…”
Get more information

Does chemotherapy-induced neutropaenia result in a postponement of adjuvant or neoadjuvant regimens in breast cancer patients? Results of a retrospective analysis by DEBLED, M, HOUEDE, N, MADRANGES, N, DONAMARIA, C, FLOQUET, A, DURAND, M, MAURIAC, Louis

“…In 2005, 224 patients received adjuvant/neoadjuvant chemotherapy for breast cancer in a single institution according to daily practices. Regimens consisted of…”
Get full text

PD-0046: Outcome according to pelvic radiotherapy in the GETUG 12 phase III trial for high-risk localized prostate cancer by Blanchard, P, Faivre, L, Lesaunier, F, Salem, N, Mesgouez-Nebout, N, Deniaud-Alexandre, E, Ferrero, J.M, Houédé, N, Habibian, M, Fizazi, K

Get full text

Professional’s expectations to improve quality of care, supportive health care and social services utilization in geriatric oncology by Antoine, V, de Wazières, B, Houédé, N

Get full text

Postoperative radiotherapy of prostate cancer by Richaud, P, Sargos, P, Henriques de Figueiredo, B, Latorzeff, I, Mongiat-Artus, P, Houédé, N, Salomon, L, Wallerand, H

“…After radical prostatectomy, the risk of biological recurrence at 5 years varies from 10 to 40 % and this natural evolution of the disease has led radiation…”
Get full text

604 Safety and Recommended Phase II Dose (RP2D) of the Selective Oral MEK1/2 Inhibitor Pimasertib (MSC1936369B/AS703026): Results of a Phase I Trial by Awada, A, Delord, J.P, Houédé, N, Lebbe, C, Lesimple, T, Schellens, J.H.M, Rottey, S, Kefford, R, Rejeb, N, Raymond, E

Get full text

616 Pimasertib (MSC1936369B/AS703026), a Selective Oral MEK1/2 Inhibitor, Shows Clinical Activity in Melanoma by Delord, J.P, Houédé, N, Awada, A, Lebbe, C, Lesimple, T, Schellens, J.H.M, Rottey, S, Kefford, R, Rejeb, N, Raymond, E

Get full text

7051 POSTER Bicalutamide in Combination With Vandetanib or Placebo in Patients With Castration-refractory Metastatic Prostate Cancer Without Any Clinical Symptom Related to Disease Progression – a Randomized, Double-blind Phase II Trial by Loriot, Y, Houédé, N, Le Moulec, S, Hennequin, C, Eymard, J.C, Beuzeboc, P, Oudard, S, Culine, S, Carrasco, A. Tisseron, Fizazi, K

Get full text

PO-170 EXCLUSIVE IODINE 125 PROSTATE BRACHYTHERAPY. EXPERIENCE OF INSTITUT BERGONIÈ by Thomas, L, Chemin, A, Belhomme, S, Lasbareilles, O, Mendiboure, J, Houédé, N, Descat, E, Monnin, D, Richaud, P

Get full text

600 Pharmacokinetics and Pharmacodynamics of a Selective Oral MEK1/2 Inhibitor, Pimasertib (MSC1936369B/AS703026), in Patients with Advanced Solid Tumors by Houédé, N, Delord, J.P, Awada, A, Lebbe, C, Lesimple, T, Schellens, J.H.M, Rottey, S, Kefford, R, von Richter, O, Raymond, E

Get full text